纳米替诺司他联合缬更昔洛韦靶向治疗复发EBV阳性淋巴系统恶性肿瘤的1b/2期研究
这项1b/2期研究评估了口服纳米替诺司他联合缬更昔洛韦治疗复发/难治性EBV阳性淋巴瘤成人患者的安全性和疗效。1b期25例确定2期推荐剂量为纳米替诺司他20 mg每日、每周4天联合缬更昔洛韦900 mg口服每日,2期30例接受该剂量。43例可评估患者总缓解率40%,完全缓解率19%,中位缓解持续时间10.4个月。
要点
- 2期推荐剂量为纳米替诺司他20 mg每日每周4天联合缬更昔洛韦900 mg口服每日,28天为一周期。
- 43例可评估患者总缓解率40%,完全缓解率19%,中位缓解持续时间10.4个月。
- 血管免疫母细胞性T细胞淋巴瘤-NHL亚组(n=15)总缓解率/完全缓解率为60%/27%。
核心结论
- 这种新型口服方案在多种EBV阳性淋巴瘤亚型中显示出令人鼓舞的疗效,值得进一步评估,一项确证性2期研究(NCT05011058)正在进行中。
研究设计与样本
- 1b/2期研究纳入年龄≥18岁、对≥1种既往全身治疗复发/难治且无可行治愈选择的EBV阳性淋巴瘤患者。
- 1b期25例患者进入5个剂量递增队列以确定2期推荐剂量,2期30例患者接受推荐剂量治疗。
- 共入组55例患者:B细胞非霍奇金淋巴瘤10例、血管免疫母细胞性T细胞淋巴瘤-NHL 21例、经典型霍奇金淋巴瘤11例、免疫缺陷相关淋巴增殖性疾病13例。
- 主要终点为安全性、推荐2期剂量确定(1b期)和总缓解率(2期)。
主要发现
- 43例可评估患者总缓解率为40%,完全缓解率19%(n=8),中位缓解持续时间10.4个月。
- 血管免疫母细胞性T细胞淋巴瘤-NHL亚组(n=15,均对末次既往治疗难治)总缓解率/完全缓解率为60%/27%。
- 最常见不良事件为恶心(任何级别38%)和血细胞减少(3/4级中性粒细胞减少29%、血小板减少20%、贫血20%)。
关键数值与推荐
- 2期推荐剂量:纳米替诺司他20 mg每日、每周4天,联合缬更昔洛韦900 mg口服每日,28天为一周期。
- 43例可评估患者总缓解率40%,完全缓解率19%(n=8),中位缓解持续时间10.4个月。
- 血管免疫母细胞性T细胞淋巴瘤-NHL亚组(n=15)总缓解率60%、完全缓解率27%。
- 3/4级中性粒细胞减少29%、血小板减少20%、贫血20%;恶心任何级别38%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lymphomas are not infrequently associated with the Epstein-Barr virus (EBV), and EBV positivity is linked to worse outcomes in several subtypes. Nanatinostat is a class-I selective oral histone deacetylase inhibitor that induces the expression of lytic EBV BGLF4 protein kinase in EBV+ tumor cells, activating ganciclovir via phosphorylation, resulting in tumor cell apoptosis. This phase 1b/2 study investigated the combination of nanatinostat with valganciclovir in patients aged ≥18 years with EBV+ lymphomas relapsed/refractory to ≥1 prior systemic therapy with no viable curative treatment options. In the phase 1b part, 25 patients were enrolled into 5 dose escalation cohorts to determine the recommended phase 2 dose (RP2D) for phase 2 expansion. Phase 2 patients (n = 30) received RP2D (nanatinostat 20 mg daily, 4 days per week with valganciclovir 900 mg orally daily) for 28-day cycles. The primary end points were safety, RP2D determination (phase 1b), and overall response rate (ORR; phase 2). Overall, 55 patients were enrolled (B-non-Hodgkin lymphoma [B-NHL], [n = 10]; angioimmunoblastic T-cell lymphoma-NHL, [n = 21]; classical Hodgkin lymphoma, [n = 11]; and immunodeficiency-associated lymphoproliferative disorders, [n = 13]). The ORR was 40% in 43 evaluable patients (complete response rate [CRR], 19% [n = 8]) with a median duration of response of 10.4 months. For angioimmunoblastic T-cell lymphoma-NHL (n = 15; all refractory to the last prior therapy), the ORR/CRR ratio was 60%/27%. The most common adverse events were nausea (38% any grade) and cytopenia (grade 3/4 neutropenia [29%], thrombocytopenia [20%], and anemia [20%]). This novel oral regimen provided encouraging efficacy across several EBV+ lymphoma subtypes and warrants further evaluation; a confirmatory phase 2 study (NCT05011058) is underway. This phase 1b/2 study is registered at www.clinicaltrials.gov as #NCT03397706.
引用
- Haverkos B, Alpdogan O, Baiocchi R, et al. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study. Blood Adv. 2023. PMID: 37530631. doi:10.1182/bloodadvances.2023010330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。